肥胖与射血分数保留的心力衰竭
Obesity and HFpEF.
作者信息
Clemenza Francesco, Citarrella Roberto, Patti Angelo, Rizzo Manfredi
机构信息
Cardiology Department, IRCCS-ISMETT, 90127 Palermo, Italy.
Promise Department, School of Medicine, University of Palermo, 90133 Palermo, Italy.
出版信息
J Clin Med. 2022 Jul 3;11(13):3858. doi: 10.3390/jcm11133858.
Abstract
Heart failure with preserved ejection fraction (HFpEF) has represented a therapeutic challenge in recent decades [...].
摘要
射血分数保留的心力衰竭（HFpEF）在近几十年来一直是一个治疗难题[……]。
相似文献
1
Obesity and HFpEF.肥胖与射血分数保留的心力衰竭
J Clin Med. 2022 Jul 3;11(13):3858. doi: 10.3390/jcm11133858.
2
Natriuretic Peptide Clearance Receptor (NPR-C) Pathway as a Novel Therapeutic Target in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF).利钠肽清除受体（NPR-C）通路作为射血分数保留的肥胖相关性心力衰竭（HFpEF）的新型治疗靶点
Front Physiol. 2021 May 21;12:674254. doi: 10.3389/fphys.2021.674254. eCollection 2021.
3
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.一种新型射血分数保留心力衰竭模式：合并症通过冠状动脉微血管内皮炎症导致心肌功能障碍和重构。
J Am Coll Cardiol. 2013 Jul 23;62(4):263-71. doi: 10.1016/j.jacc.2013.02.092. Epub 2013 May 15.
4
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.应变成像技术评估射血分数保留心力衰竭患者的收缩功能障碍。
J Am Coll Cardiol. 2014 Feb 11;63(5):447-56. doi: 10.1016/j.jacc.2013.09.052. Epub 2013 Oct 30.
5
Knockout of MD1 contributes to sympathetic hyperactivity and exacerbates ventricular arrhythmias following heart failure with preserved ejection fraction via NLRP3 inflammasome activation.敲除 MD1 可导致射血分数保留型心力衰竭后交感神经活性亢进，并通过 NLRP3 炎性小体激活加重室性心律失常。
Exp Physiol. 2020 Jun;105(6):966-978. doi: 10.1113/EP088390. Epub 2020 May 6.
6
Effective blood hemoglobin level to predict prognosis in heart failure with preserved left ventricular ejection fraction: results of the Japanese heart failure syndrome with preserved ejection fraction registry.预测左心室射血分数保留的心力衰竭预后的有效血红蛋白水平：日本射血分数保留的心力衰竭综合征注册研究结果
Heart Vessels. 2019 Jul;34(7):1168-1177. doi: 10.1007/s00380-019-01349-6. Epub 2019 Jan 24.
7
Treatment of Heart Failure with Preserved Ejection Fraction.射血分数保留型心力衰竭的治疗。
Adv Exp Med Biol. 2018;1067:67-87. doi: 10.1007/5584_2018_149.
8
Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction.体力活动、身体适能与射血分数保留型心力衰竭伴发肥胖。
JACC Heart Fail. 2018 Dec;6(12):975-982. doi: 10.1016/j.jchf.2018.09.006.
9
Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity.射血分数保留的心力衰竭患者的生活质量：肥胖、功能能力和体力活动不足的重要性。
Eur J Heart Fail. 2020 Jun;22(6):1009-1018. doi: 10.1002/ejhf.1788. Epub 2020 Mar 9.
10
Cardiomyocyte Functional Etiology in Heart Failure With Preserved Ejection Fraction Is Distinctive-A New Preclinical Model.心肌细胞功能病因在射血分数保留心力衰竭中有独特表现——一种新的临床前模型。
J Am Heart Assoc. 2018 Jun 1;7(11):e007451. doi: 10.1161/JAHA.117.007451.
引用本文的文献
1
Machine learning algorithms to predict heart failure with preserved ejection fraction among patients with premature myocardial infarction.用于预测心肌梗死患者射血分数保留的心力衰竭的机器学习算法。
Front Cardiovasc Med. 2025 May 7;12:1571185. doi: 10.3389/fcvm.2025.1571185. eCollection 2025.
2
Obesity and cardiovascular disease: Risk assessment, physical activity, and management of complications.肥胖与心血管疾病：风险评估、体育活动及并发症管理
Int J Cardiol Cardiovasc Risk Prev. 2024 Sep 5;23:200331. doi: 10.1016/j.ijcrp.2024.200331. eCollection 2024 Dec.
3
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?胰高血糖素样肽-1受体激动剂在射血分数保留的肥胖相关性心力衰竭管理中的新作用：益处超乎体重秤所能衡量？
Biomedicines. 2024 Sep 16;12(9):2112. doi: 10.3390/biomedicines12092112.
4
Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction.超越体重减轻：胰高血糖素样肽-1受体激动剂治疗射血分数保留的心力衰竭的潜力
Heart Fail Rev. 2025 Jan;30(1):17-38. doi: 10.1007/s10741-024-10438-2. Epub 2024 Sep 13.
5
Systematic review and meta-analysis to predict mortality in heart failure with preserved ejection fraction: Development and validation of the HF-DANAS score.预测射血分数保留的心力衰竭患者死亡率的系统评价和荟萃分析：HF-DANAS评分的开发与验证
ESC Heart Fail. 2024 Dec;11(6):4104-4115. doi: 10.1002/ehf2.15008. Epub 2024 Aug 8.
6
Obesity and metabolic syndrome in patients with heart failure with preserved ejection fraction: a cross-sectional analysis of the Veradigm Cardiology Registry.射血分数保留的心力衰竭患者中的肥胖和代谢综合征：Veradigm 心脏病学注册中心的横断面分析。
BMC Endocr Disord. 2024 May 1;24(1):59. doi: 10.1186/s12902-024-01589-2.
7
Epicardial adipose tissue in obesity with heart failure with preserved ejection fraction: Cardiovascular magnetic resonance biomarker study.射血分数保留的肥胖合并心力衰竭患者的心外膜脂肪组织：心血管磁共振生物标志物研究
World J Cardiol. 2024 Mar 26;16(3):149-160. doi: 10.4330/wjc.v16.i3.149.
8
GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI.GLP-1RA 对 ASCVD 患者的心脏结构可能有不同的影响，这取决于 BMI。
Front Endocrinol (Lausanne). 2024 Mar 15;15:1355540. doi: 10.3389/fendo.2024.1355540. eCollection 2024.
9
The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest.SGLT-2抑制剂在急性心力衰竭中的治疗作用：从病理生理机制到临床证据，并对相关研究在感兴趣的安全性和有效性终点进行汇总分析
Life (Basel). 2022 Dec 8;12(12):2062. doi: 10.3390/life12122062.
本文引用的文献
1
Immunometabolic Mechanisms of Heart Failure with Preserved Ejection Fraction.射血分数保留的心力衰竭的免疫代谢机制
Nat Cardiovasc Res. 2022 Mar;1(3):211-222. doi: 10.1038/s44161-022-00032-w. Epub 2022 Mar 14.
2
Epicardial adipose tissue in contemporary cardiology.心脏外膜脂肪组织在当代心脏病学中的应用
Nat Rev Cardiol. 2022 Sep;19(9):593-606. doi: 10.1038/s41569-022-00679-9. Epub 2022 Mar 16.
3
Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.通过 GLP-1 受体激动剂和 SGLT2 抑制剂调节心外膜脂肪来降低心血管风险。
J Endocrinol Invest. 2022 Mar;45(3):489-495. doi: 10.1007/s40618-021-01687-1. Epub 2021 Oct 13.
4
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.利拉鲁肽对心血管高危超重和肥胖成人内脏和异位脂肪的影响：一项随机、双盲、安慰剂对照的临床试验。
Lancet Diabetes Endocrinol. 2021 Sep;9(9):595-605. doi: 10.1016/S2213-8587(21)00179-0. Epub 2021 Aug 3.
5
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.司美格鲁肽对超重或肥胖患者心血管结局的影响（SELECT）：基本原理和设计。
Am Heart J. 2020 Nov;229:61-69. doi: 10.1016/j.ahj.2020.07.008. Epub 2020 Jul 17.
6
Metabolic inflammation in heart failure with preserved ejection fraction.射血分数保留的心力衰竭中的代谢炎症。
Cardiovasc Res. 2021 Jan 21;117(2):423-434. doi: 10.1093/cvr/cvaa217.
7
Regional adiposity and heart failure with preserved ejection fraction.区域性肥胖与射血分数保留型心力衰竭。
Eur J Heart Fail. 2020 Sep;22(9):1540-1550. doi: 10.1002/ejhf.1956. Epub 2020 Aug 5.
8
Unfolding Discoveries in Heart Failure.心力衰竭领域不断涌现的新发现
N Engl J Med. 2020 Feb 13;382(7):679-682. doi: 10.1056/NEJMcibr1913825.
9
Nitrosative stress drives heart failure with preserved ejection fraction.硝化应激导致射血分数保留型心力衰竭。
Nature. 2019 Apr;568(7752):351-356. doi: 10.1038/s41586-019-1100-z. Epub 2019 Apr 10.
10
Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction.体力活动、身体适能与射血分数保留型心力衰竭伴发肥胖。
JACC Heart Fail. 2018 Dec;6(12):975-982. doi: 10.1016/j.jchf.2018.09.006.
Zotero 插件